~~<i id='BA0C7A59E7'><strike id='BA0C7A59E7'><tt id='BA0C7A59E7'><pre id='BA0C7A59E7'></pre></tt></strike></i>~~

Home» knowledge» entertainment

entertainment

author：explore 2025-08-27 20:46:01 Page View：3

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

comprehensive

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Research misconduct: Proposed new rules face resistance

AdobeResearchuniversitiesarevoicingconcernsoversomeproposedchangestotheprocessforreviewingscientific

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

4 dead, 2 in stable condition in Philadelphia shooting: Police

1:31Policelightsonastreetatnight.STOCKPHOTO/GettyImagesFourpeoplearedeadandtwoarehospitalizedinstabl